USANA HEALTH SCIENCES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that USANA HEALTH SCIENCES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 28, 2019 | $271.30M | Feb 25, 2020 |
| FY2019 | Sep 28, 2019 | $260.60M | Feb 25, 2020 |
| FY2019 | Jun 29, 2019 | $256.02M | Feb 25, 2020 |
| FY2019 | Mar 30, 2019 | $272.99M | Feb 25, 2020 |
| FY2019 | Dec 29, 2018 | $299.02M | Feb 25, 2020 |
| FY2019 | Sep 29, 2018 | $296.77M | Feb 25, 2020 |
| FY2019 | Jun 30, 2018 | $301.46M | Feb 25, 2020 |
| FY2019 | Mar 31, 2018 | $292.00M | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $273.11M | Feb 26, 2019 |
| FY2018 | Sep 30, 2017 | $261.77M | Feb 26, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $925.26M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $854.50M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $921.01M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $998.60M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $1.19B | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $1.13B | Feb 28, 2023 |
| FY2022 | Dec 28, 2019 | $1.06B | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $1.19B | Mar 2, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $724.41M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $693.29M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $744.32M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $804.71M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $968.57M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $925.53M | Feb 28, 2023 |
| FY2019 | Dec 28, 2019 | $224.01M | Feb 25, 2020 |
| FY2019 | Sep 28, 2019 | $212.78M | Feb 25, 2020 |
| FY2019 | Jun 29, 2019 | $209.52M | Feb 25, 2020 |
| FY2019 | Mar 30, 2019 | $227.09M | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $10.76M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $42.03M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $63.79M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $69.35M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $116.51M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $124.66M | Feb 28, 2023 |
| FY2019 | Dec 28, 2019 | $30.75M | Feb 25, 2020 |
| FY2019 | Sep 28, 2019 | $24.22M | Feb 25, 2020 |
| FY2019 | Jun 29, 2019 | $21.38M | Feb 25, 2020 |
| FY2019 | Mar 30, 2019 | $24.17M | Feb 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $37.43M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $66.32M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $93.07M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $107.61M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $170.19M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $176.49M | Feb 28, 2023 |
| FY2022 | Dec 28, 2019 | $146.19M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $188.35M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $132.50M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $138.62M | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $10.69M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $11.57M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $11.45M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $11.56M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $11.11M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $10.63M | Feb 28, 2023 |
| FY2022 | Dec 28, 2019 | $10.26M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $10.24M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $8.95M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $8.84M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $337.37M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $263.27M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $256.99M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $262.30M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $279.11M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $261.19M | Feb 28, 2023 |
| FY2022 | Dec 28, 2019 | $267.73M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $275.06M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $265.09M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $234.19M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $22.35M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $60.99M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $70.64M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $103.90M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $121.23M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $160.40M | Feb 28, 2023 |
| FY2022 | Dec 28, 2019 | $126.73M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $152.12M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $123.77M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $136.89M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $13.82M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $10.07M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $14.49M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $10.40M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $12.76M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $15.09M | Feb 28, 2023 |
| FY2022 | Dec 28, 2019 | $16.57M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $11.43M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $13.22M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $32.70M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $742.92M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $748.19M | Mar 16, 2026 |
| FY2023 | Dec 30, 2023 | $632.76M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $596.55M | Feb 27, 2024 |
| FY2022 | Jan 1, 2022 | $577.74M | Feb 28, 2023 |
| FY2022 | Jan 2, 2021 | $640.89M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $516.93M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $554.46M | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $519.27M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $470.64M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $156.64M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $161.86M | Mar 16, 2026 |
| FY2023 | Dec 30, 2023 | $135.56M | Mar 12, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $533.10M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $532.11M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $497.20M | Mar 16, 2026 |
| FY2025 | Dec 31, 2022 | $434.47M | Mar 16, 2026 |
| FY2023 | Jan 1, 2022 | $395.12M | Mar 12, 2025 |
| FY2023 | Jan 2, 2021 | $441.65M | Feb 27, 2024 |
| FY2022 | Dec 28, 2019 | $351.71M | Feb 28, 2023 |
| FY2022 | Dec 29, 2018 | $391.15M | Mar 1, 2022 |
| FY2020 | Dec 30, 2017 | $363.21M | Mar 2, 2021 |
| FY2019 | Dec 31, 2016 | $325.29M | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $137.96M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $144.17M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $17.10M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $17.37M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $17.67M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $17.37M | Feb 28, 2023 |
| FY2022 | Dec 28, 2019 | $16.64M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $16.82M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $17.42M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $16.72M | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $465.72M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $478.94M | Mar 16, 2026 |
| FY2023 | Dec 30, 2023 | $445.22M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $391.64M | Feb 27, 2024 |
| FY2022 | Jan 1, 2022 | $344.64M | Feb 28, 2023 |
| FY2022 | Jan 2, 2021 | $382.79M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $306.15M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $329.50M | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $288.07M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $265.41M | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $158.38M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | $181.77M | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | $330.42M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $288.42M | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | $239.83M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $311.92M | Feb 28, 2023 |
| FY2022 | Dec 28, 2019 | $234.83M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $214.33M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $247.13M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $175.77M | Feb 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 0 | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | 2 | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | 3 | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | 3 | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | 5 | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | 5 | Feb 28, 2023 |
| FY2019 | Dec 28, 2019 | 1 | Feb 25, 2020 |
| FY2019 | Sep 28, 2019 | 1 | Feb 25, 2020 |
| FY2019 | Jun 29, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Mar 30, 2019 | 1 | Feb 25, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 0 | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | 2 | Mar 16, 2026 |
| FY2025 | Dec 30, 2023 | 3 | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | 3 | Mar 12, 2025 |
| FY2023 | Jan 1, 2022 | 5 | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | 5 | Feb 28, 2023 |
| FY2019 | Dec 28, 2019 | 1 | Feb 25, 2020 |
| FY2019 | Sep 28, 2019 | 1 | Feb 25, 2020 |
| FY2019 | Jun 29, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Mar 30, 2019 | 1 | Feb 25, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 18.28M | Mar 16, 2026 |
| FY2025 | Dec 28, 2024 | 19.06M | Mar 16, 2026 |
| FY2023 | Dec 30, 2023 | 19.13M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 19.21M | Feb 27, 2024 |
| FY2022 | Jan 1, 2022 | 19.39M | Feb 28, 2023 |
| FY2022 | Jan 2, 2021 | 21.04M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | 21.66M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | 23.57M | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | 24.02M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 24.49M | Feb 28, 2018 |